Uveal Melanoma - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 93
   

Global Markets Direct’s, ‘Uveal Melanoma - Pipeline Review, H2 2015’, provides an overview of the Uveal Melanoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveal Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Uveal Melanoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Uveal Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Uveal Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Uveal Melanoma - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Uveal Melanoma Overview 8
Therapeutics Development 9
Pipeline Products for Uveal Melanoma - Overview 9
Pipeline Products for Uveal Melanoma - Comparative Analysis 10
Uveal Melanoma - Therapeutics under Development by Companies 11
Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 12
Uveal Melanoma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Uveal Melanoma - Products under Development by Companies 16
Uveal Melanoma - Products under Investigation by Universities/Institutes 17
Uveal Melanoma - Companies Involved in Therapeutics Development 18
Aura Biosciences, Inc. 18
Celldex Therapeutics, Inc. 19
Eli Lilly and Company 20
GlaxoSmithKline Plc 21
Immunocore Limited 22
Navigen Pharmaceuticals, Inc. 23
Novartis AG 24
PEP-Therapy SAS 25
Pfizer Inc. 26
Spectrum Pharmaceuticals, Inc. 27
Uveal Melanoma - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AU-011 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
axitinib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
crizotinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Dendritic Cell Therapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DPTPEP-1 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
emibetuzumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
glembatumumab vedotin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IMCgp100 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
KCN-1 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
merestinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NAV-2729 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
nutlin-3 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
pasireotide LAR - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
sunitinib malate - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Vaccine 2 for Melanoma - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
vincristine sulfate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Uveal Melanoma - Recent Pipeline Updates 73
Uveal Melanoma - Dormant Projects 90
Uveal Melanoma - Discontinued Products 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93

List of Tables

Number of Products under Development for Uveal Melanoma, H2 2015 9
Number of Products under Development for Uveal Melanoma - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Uveal Melanoma - Pipeline by Aura Biosciences, Inc., H2 2015 18
Uveal Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2015 19
Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2015 20
Uveal Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2015 21
Uveal Melanoma - Pipeline by Immunocore Limited, H2 2015 22
Uveal Melanoma - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015 23
Uveal Melanoma - Pipeline by Novartis AG, H2 2015 24
Uveal Melanoma - Pipeline by PEP-Therapy SAS, H2 2015 25
Uveal Melanoma - Pipeline by Pfizer Inc., H2 2015 26
Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 27
Assessment by Monotherapy Products, H2 2015 28
Assessment by Combination Products, H2 2015 29
Number of Products by Stage and Target, H2 2015 31
Number of Products by Stage and Mechanism of Action, H2 2015 34
Number of Products by Stage and Route of Administration, H2 2015 36
Number of Products by Stage and Molecule Type, H2 2015 38
Uveal Melanoma Therapeutics - Recent Pipeline Updates, H2 2015 73
Uveal Melanoma - Dormant Projects, H2 2015 90
Uveal Melanoma - Discontinued Products, H2 2015 91

List of Figures

Number of Products under Development for Uveal Melanoma, H2 2015 9
Number of Products under Development for Uveal Melanoma - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Products, H2 2015 15
Assessment by Monotherapy Products, H2 2015 28
Number of Products by Top 10 Targets, H2 2015 30
Number of Products by Stage and Top 10 Targets, H2 2015 30
Number of Products by Top 10 Mechanism of Actions, H2 2015 33
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 33
Number of Products by Top 10 Routes of Administration, H2 2015 35
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 35
Number of Products by Top 10 Molecule Types, H2 2015 37
Number of Products by Stage and Top 10 Molecule Types, H2 2015 37

Published By: Global Markets Direct
Product Code: Global Markets Direct13347


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: